Romaldas Mačiulaitis

Dr. Romaldas Mačiulaitis


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2023 in Cells
Verified
Journal Article
Open access
PDF file
Paulius ValiukeviciusPaulius Valiukevicius
Paulius Valiukevicius
JMJustinas Mačiulaitis
Justinas Mačiulaitis
DPDalia Pangonytė
Dalia Pangonytė
VSVitalija Siratavičiūtė
Vitalija Siratavičiūtė
KKKatarzyna Anna Kluszczynska
Katarzyna Anna Kluszczynska
RMRomaldas Mačiulaitis
Romaldas Mačiulaitis
This study investigates the therapeutic potential of human placental mesenchymal stem cells (P-MSCs) and their extracellular vesicles (EVs) in a murine model of acute respiratory distress syndrome (ARDS), a condition with growing relevance due to its association with severe COVID-19. We induced ARDS-like lung injury in mice using intranasal LPS instillation and evaluated histological changes, neutrophil accumulation via immunohistochemistry, bronchoalveolar lavage fluid cell count, total protein, and cytokine concentration, as well as lung gene expression changes at three time points: 24, 72, and 168 h. We found that both P-MSCs and EV treatments reduced the histological evidence of lung injury, decreased neutrophil infiltration, and improved alveolar barrier integrity. Analyses of cytokines and gene expression revealed that both treatments accelerated inflammation resolution in lung tissue. Biodistribution studies indicated negligible cell engraftment, suggesting that intraperitoneal P-MSC therapy functions mostly through soluble factors. Overall, both P-MSC and EV therapy ameliorated LPS-induced lung injury. Notably, at the tested dose, EV therapy was more effective than P-MSCs in reducing most aspects of lung injury.

5 November 2025 in Medicina
Verified
Journal Article
Open access
PDF file
SŽSkaistė Žukaitienė
Skaistė Žukaitienė
KBKarolis Bareikis
Karolis Bareikis
SSSimona Stankeviciute
Simona Stankeviciute
AUAkvile Usaite
Akvile Usaite
NBNeringa Balčiūnienė
Neringa Balčiūnienė
RMRomaldas Mačiulaitis
Romaldas Mačiulaitis
Background and Objectives: Post-surgical central nervous system (CNS) infections are severe complications associated with high morbidity and mortality. Vancomycin is a key antibiotic used in their management. However, because of the restrictive properties of the blood–brain barrier (BBB), plasma concentrations may not accurately reflect drug exposure in the brain extracellular fluid (ECF), the presumed site of infection. Cerebral microdialysis enables direct measurement of unbound drug levels in brain ECF. This study aimed to assess vancomycin penetration into brain ECF in patients with suspected or confirmed post-surgical CNS infection. Materials and Methods: Five patients with suspected or confirmed post-surgical CNS infections were enrolled. Paired brain ECF microdialysate and plasma samples (and cerebrospinal fluid (CSF) samples, when available) were collected over two consecutive days at vancomycin steady state. Vancomycin concentrations were determined using a homogeneous enzyme immunoassay and corrected for probe recovery based on in vitro calibration. Pharmacokinetic parameters, including mean concentrations and 24-h area under the concentration–time curve (AUC24), were calculated for plasma and ECF, and ECF-to-plasma ratios were derived. Results: Two subgroups could be identified: patients with negligible ECF concentrations (“low penetrators”), and those with higher ECF levels (“high penetrators”). Mean (SD) ECF-to-plasma concentration ratios were 0.07 (0.04) in “low penetrators” and 0.44 (0.10) in “high penetrators”. The corresponding AUC24 ratios were 0.06 (0.03) and 0.40 (0.03), respectively. The presence of systemic inflammatory response syndrome (SIRS) was considered the most plausible factor differentiating these two subgroups. Conclusions: Vancomycin exposure in brain ECF demonstrated substantial interpatient variability in post-surgical CNS infections, with some patients showing minimal drug penetration.

Verified
Journal Article
Open access
PDF file
AGAgnė Gryguc
Agnė Gryguc
JMJustinas Maciulaitis
Justinas Maciulaitis
LMLukas Mickevicius
Lukas Mickevicius
ALArvydas Laurinavicius
Arvydas Laurinavicius
NSNeringa Sutkevičienė
Neringa Sutkevičienė
Inga Arune BumblyteInga Arune Bumblyte
Inga Arune Bumblyte
Acute kidney injury (AKI) is widely recognized as a precursor to the onset or rapid progression of chronic kidney disease (CKD). However, there is currently no effective treatment available for AKI, underscoring the urgent need for the development of new strategies to improve kidney function. Human placental mesenchymal stromal cells (hpMSCs) were isolated from donor placentas, cultured, and characterized with regard to yield, viability, flow cytometry, and potency. To mimic AKI and its progression to CKD in a rat model, a dedicated sensitive non-clinical bilateral kidney ischemia-reperfusion injury (IRI) model was utilized. The experimental group received 3 × 105 hpMSCs into each kidney, while the control group received IRI and saline and the untreated group received IRI only. Urine, serum, and kidney tissue samples were collected over a period of 28 days. The hpMSCs exhibited consistent yields, viability, and expression of mesenchymal lineage markers, and were also shown to suppress T cell proliferation in a dose-dependent manner. To ensure optimal donor selection, manufacturing optimization, and rigorous quality control, the rigorous Good Manufacturing Practice (GMP) conditions were utilized. The results indicated that hpMSCs increased rat survival rates and improved kidney function by decreasing serum creatinine, urea, potassium, and fractionated potassium levels. Furthermore, the study demonstrated that hpMSCs can prevent the initial stages of kidney structural fibrosis and improve kidney function in the early stages by mitigating late interstitial fibrosis and tubular atrophy. Additionally, a robust manufacturing process with consistent technical parameters was established.

21 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
SŽSkaistė Žukaitienė
Skaistė Žukaitienė
KBKarolis Bareikis
Karolis Bareikis
SSSimona Stankevičiūtė
Simona Stankevičiūtė
AŪAkvilė Ūsaitė
Akvilė Ūsaitė
JPJolita Pancerė
Jolita Pancerė
RMRomaldas Mačiulaitis
Romaldas Mačiulaitis
Background/Objectives: Postoperative central nervous system (CNS) infections are severe compli-cations of neurosurgery, and vancomycin is a cornerstone of empirical and targeted therapy; how-ever, longitudinal vancomycin exposure in this population is poorly characterized. Methods: We conducted a single-centre retrospective cohort study of 189 postoperative CNS infection episodes in 174 adults treated between 2020 and 2026, focusing on longitudinal vancomycin exposure and pharmacokinetic.pharmacodynamic (PK/PD) target attainment according to therapeutic drug mon-itoring (TDM) status. A population pharmacokinetic (PopPK) model, developed from 193 concen-trations was used to reconstruct exposure in TDM episodes and simulate exposure for no TDM ep-isodes. Results: The final PopPK model confirmed creatinine clearance (CrCl) as the principal de-terminant of vancomycin clearance; higher baseline CrCl independently predicted a greater propor-tion of treatment time with AUC24 <400 mg·h/L. Underexposure occurred throughout: patients spent 37.2% (TDM) and 47.5% (no TDM) of evaluable treatment time below AUC24 400 mg·h/L, with early underexposure even more common in both groups. The TDM group spent more time within the AUC₂₄ 400–600 mg·h/L range (43.23% vs 29.91%). No statistically significant exposure–outcome associations were identified in the overall population. In an exploratory ICU subgroup analysis, higher mean AUC₂₄ was associated with clinical improvement within 72 h (OR 1.92 per 100 mg·h/L increase, 95% CI 1.12–3.28), although the exposure-by-ICU interaction was not statistically signifi-cant. Conclusions: These findings support early and repeated vancomycin TDM throughout treat-ment to identify and address underexposure, particularly in patients with augmented renal function and those treated in ICU.